Background {#Sec1}
==========

Overgrowth with multiple birth defects is useful phenotypic sign in diagnostic categorization of congenital diseases. Overgrowth syndromes (OGSs) are a group of heterogeneous disorders including Sotos syndrome (SOTOS1, OMIM\#117550), Beckwith-Wiedemann syndrome (BWS; OMIM\#130650), Simpson-Golabi-Behmel syndrome (SGBS1, OMIM\#312870), Proteus syndrome (PS, OMIM\#176920), Bannayan-Riley-Ruvalcaba syndrome (BRRS, OMIM\#153480) and Weaver Syndrome (WVS, OMIM \#277590) \[[@CR1]\]. Recently the molecular causes of several OGSs have been revealed \[[@CR2]\]. Despite these advances, the underlying genetic mechanisms for 20--40 % of overgrowth individuals remain unknown \[[@CR2]\].

Malan syndrome, also named as Sotos-like syndrome or Sotos syndrome 2 (SOTOS2, OMIM\#614753), is a recently introduced clinical condition characterized by tall stature, intellectual disability and/or macrocephaly \[[@CR2]--[@CR4]\]. This syndrome has been associated with the *NFIX* gene on chromosomal locus 19p13.2. *NFIX* encodes the nuclear factor I X (CCAAT-binding transcription factor) protein \[[@CR5]\]. It has been suggested that either a nonsense mutation in the *NFIX* gene or microdeletion encompassing *NFIX* underlies this syndrome \[[@CR2], [@CR6]\].

As part of a larger study on the identification of pathogenic copy number variations in children with birth defects, four overgrowth children carrying multiple birth defects with undetermined genetic reasons were enrolled in this study. High-resolution SNP-array analysis (Illumina, San Diego, CA, USA) was performed to analyze the genomes of these patients. Here, we present two patients with overgrowth syndromes, Patient 1 was diagnosed as Malan syndrome with a 1.4 Mb deletion in chromosomal region 19p13.2-13.13, and Patient 2 was identified as Sotos syndrome with a 1.6 Mb 5q35.2 microdeletion.

Clinical report {#Sec2}
===============

Patient 1 {#Sec3}
---------

This male patient was two-year and seven-month old at the time of genetic evaluation. He was the second child of a healthy unrelated couple. Family history of birth defects or genetic disorders was denied. He was born at 39 weeks of gestation by normal delivery. His birth weight was 4000 g (75-90th centile) with a birth length of 51 cm (50th centile) and a head circumference of 37 cm (75--90th centile). Due to respiratory failure, the patient was treated with intubation and artificial respiration and admitted to the neonatal intensive care unit (NICU). At six months, he attended to the Second Xiangya Hospital because of development delay. At this time, he weighed 8000 g (75--90th centile) with a length of 72 cm (50th centile) and a head circumference of 43 cm (75--90th centile). Mildly reduced volume of the white matter, and the thin corpus callosum were revealed by brain MRI. Electroencephalogram (EEG) showed no definite abnormality. At present, his length is 79 cm (50th centile), weight 12 kg (50th centile) and OFC 48.6 cm (75--90th centile), suggesting that his head is relatively large compared with his stature. He showed frontal bossing, high forehead, deep-set eyes, sparse eyebrows, a flat nasal bridge, low-set ears, high-arched palate, bilateral strabismus and pectus excavatum (Fig. [1](#Fig1){ref-type="fig"}). He could not sit up and walk by himself. Also he could not speak any meaningful words. His psychomotor development was evaluated by the GESELL Developmental Diagnosis Scale (GDDS) and the developmental quotient (DQ) was determined to be 19. Neurological examination revealed generalized hypotonia and reduced deep tendon reflexes. Peripheral nerve conduction velocities showed no abnormalities. Conventional G-banding analyses showed no abnormalities.Fig. 1Clinical photographs of the probands. **a**: Patient 1 with Malan syndrome shows frontal bossing, high forehead, deep-set eyes, sparse eyebrows, a flat nasal bridge, low-set ears, high-arched palate, and bilateral strabismus. **b**, **c**: lateral view of the Patient 2 with Sotos syndrome. Frontal bossing, high forehead, deep-set eyes, heterochromia and congenital microphthalmia were observed

Patient 2 {#Sec4}
---------

The patient was referred to the genetic service at the age of three years with intellectual disability, macrocephaly and congenital heart defect (patent ductus arteriosus, PDA). This girl was born to non-consanguineous, healthy parents. At her birth, her mother and father were both at 36 years old. She was born by cesarean at 39 weeks plus 4 days with a birth weight 3,780 g (70--90th centile); birth length of 52 cm (90th centile) and a head circumstance of 36.8 cm. Frontal bossing, high forehead, deep-set eyes and congenital heart disease were observed. Eye anomalies, heterochromia and congenital microphthalmia were also observed. Conventional G-banding analyses showed no abnormalities.

Patient 3 {#Sec5}
---------

Patient 3 attended to our hospital due to congenital heart disease. Family history was absent. He was six-year old and had several distinct phenotypes, i.e. ASD (atrial septal defect), tall stature and behavior problems (self-hugging and frequent temper outbursts).

Patient 4 {#Sec6}
---------

This patient was a five-year old boy. He was the second child of unrelated parents without obvious family history of inherited disease. Congenital heart defect (PDA), frontal bossing and high forehead, macrocephaly, big toe and also behavior problems (impulsiveness, frequent temper tantrums and outbursts) were observed.

Methods {#Sec7}
=======

The Review Board of the Second Xiangya Hospital of the Central South University approved this study. All subjects consented to this study.

Chromosome analysis was performed on peripheral blood of the patient and the parents by conventional G-banded techniques (550-band resolution). 5 ml peripheral blood was collected for each individual. All samples were subjected to lymphocyte culture according to standard cytogenetic protocol.

The genomic DNA was prepared from peripheral blood of the patient and the parents. Genomic DNA was prepared using a DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) on the QIAcube automated DNA extraction robot (Qiagen, Hiden, Germany).

Genomic DNA samples of the patient and parents were adjusted to a final concentration of 50 ng/μl. The HumanOmni1-Quad Chip (Illumina Inc., San Diego, USA) and the Illumina BeadScan genotyping system (Beadstation Scanner) were employed to obtain the signal intensities of SNP probes \[[@CR7], [@CR8]\]. Human Omni1-Quad Beadchip contains over 1.1 million loci across the human genome. The GenomeStudio V2011 software was used to analyze the genotypes (human genome build 37/Hg19 for analysis) and evaluate the experimental quality. The call rates of the samples are greater than 99.5 %.

Results {#Sec8}
=======

Conventional G-banding analyses showed no abnormalities in four children with overgrowth syndromes. To identify the patients\' genetic lesions, we employed SNP-array system (HumanOmni1-Quad Chip) to analyze the possibility of pathogenic copy number variations (pCNVs). A *de novo* 1.4 Mb deletion ranging from 19p13.2 to 19p13.13 (chr19: 12,157,839-13,518,462/hg19) was identified in Patient 1 with unique clinical phenotypes i.e. macrocephaly, overgrowth and intellectual disability. This chromosome region is gene-rich and contains several OMIM genes *NFIX*, *CACNA1A* and *CAL*R (Fig. [2](#Fig2){ref-type="fig"}). Consistent with previous reports that deletions of 19p13.2 are associated with overgrowth and other abnormalities, this patient got a clinically diagnosis as Malan syndrome (19p13.2 microdeletion syndrome). In addition, a *de novo* 1.6 Mb deletion on chromosomal locus 5q35.2 encompassing *NSD1* (chr5:175,548,190-177,145,695/hg19) was revealed in Patient 2 with Sotos syndrome. SNP-array analysis showed no pathogenic deletions or duplications in Patient 3 and Patient 4, hence these two patients remain undiagnosed.Fig. 2Human Omni1-Quad SNP-array result of the 19p13.2-p13.13 in Patient 1 with Malan syndrome. SNP-based array shows a *de novo* 1.4 Mb deletion (chr19: 12,157,839-13,518,462/hg19). Log R ratio and B allele frequencies are showed in upper panel; the lower panel shows genes in the deleted region

Discussion {#Sec9}
==========

Overgrowth syndromes are a group of conditions with heterogeneity and share several cardinal clinical features, i.e., overgrowth, intellectual disability and/or macrocephaly. The complexity of phenotypic features makes the differential diagnoses of overgrowth syndromes difficult. Recent advances in genetic studies have facilitated the molecular delineation of overgrowth syndromes. As a result, several overgrowth syndromes have been genetically elucidated in last decade. In this study, we report two patients with distinct overgrowth syndromes, Malan syndrome (19p13.2 deletion of *NFIX*) and Sotos Syndrome (5q35.2 deletion of *NSD1*).

In 2010, Malan et al. combined chromosomal microarrays and candidate gene approaches and successfully discovered nonsense mutations or microdeletion of *NFIX* in patients with Sotos-like overgrowth syndrome \[[@CR6]\]. Mutations in *NFIX* had been linked to a known clinical condition, Marshall-Smith syndrome (MSS, OMIM\#602535)\[[@CR9]\]. It is suggested that different types of *NFIX* variants underlie distinct clinical phenotypes \[[@CR6]\]. Specifically, frameshift and splice mutations in *NFIX* resulted in Marshall-Smith syndrome (MSS) while *NFIX* deletions and nonsense mutations cause a Sotos-like overgrowth syndrome. This phenomenon that distinct mutations result in strikingly different phenotypes has also been observed in other syndromes i.e. *PTEN* mutations cause Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome (BRRS) and Proteus syndrome (PS)\[[@CR10]\], while *FBN1* underlies Marfan syndrome, Weill-Marchesani syndrome (WMS) and acromicric dysplasia.\[[@CR11], [@CR12]\]. Subsequently, several reports confirmed *NFIX* mutations in patients with Sotos syndrome-like features resembling the patients previously reported by Malan et al. \[[@CR2], [@CR3], [@CR13], [@CR14]\]. In 2015, Klaassens et al., reported six additional patients with point mutation or deletion of *NFIX* \[[@CR2]\]. Literature review of patients with 19p13.2-19p13.13 deletions showed similar clinical features \[[@CR15]--[@CR20]\]. Finally this medical condition was collectively grouped as Malan syndrome (19p13.2 deletion syndrome).

Common and prominent features are shared by different types of overgrowth syndromes, which imply that these syndromes might share similar molecular mechanisms. Since the two overgrowth disease-related genes, *NFIX* and *NSD1*, are both transcription factor, we suspect that they might be involved in similar molecular processes. The transcription factor nuclear factor I X plays a pivotal role during the development of brain and skeleton \[[@CR5]\]. The Nfix(-/-) mice have retarded growth and most would die after postnatal day 21 (P21) in addition to malformations in brain ventricles and the corpus callosum \[[@CR5]\]. *NSD1* encodes a protein containing a SET domain, four plant homeodomain (PHD) finger regions and a proline-rich region. The SET Domain of NSD1 protein has intrinsic histone methyltransferase activity \[[@CR21]\]. Based on these observations, Sotos syndrome and Sotos-like overgrowth syndrome have been suggested to be epigenetic diseases caused by loss-of-function defects of epigenetic readers/writers that modify the H3K36 histone mark \[[@CR22]\]. Consistent with this idea, mutations in the DNA methyltransferase gene *DNMT3A*, *SETD2* and *EZH2* have also been shown to cause overgrowth syndromes \[[@CR22]--[@CR24]\]. Most recent *NFIX* function studies focus on its role in the brain malformations, whether *NFIX* is involved in epigenetic regulation remains to be elucidated \[[@CR25], [@CR26]\].

The discovery of *NFIX* as a causal gene for Malan syndrome also provides a success example for the microarrays-based candidate gene strategy in the identification of Mendelian disease-genes. Various mapping approaches rely upon karyotyping, linkage analysis, homozygosity mapping, GWAS and the recently introduced chromosomal microarrays (copy number variation analysis) and WES/WGS (whole exome/genome sequencing) \[[@CR27]\]. An overview of literatures suggests that 13 disease-causing genes have been successfully identified by microarrays-based approaches including array CGH and SNP-array (Table [1](#Tab1){ref-type="table"}). The disease gene number is relatively small but shows great growing potential. More importantly, with the accumulated copy number variation database, microarrays-based candidate gene strategy would be more productive in combination with exome sequencing data (Next Generation Sequencing, NGS).Table 1Mendelian causative genes identified by the microarrays-based candidate gene strategyGeneLocusSize (kb)Syndrome/phenotypeYearReference*RAI1*17p11.24000Smith--Magenis syndrome2003Nat Genet.2003; 33:466-8.*CHD7*8q122300CHARGE syndrome2004Nat Genet. 2004; 36:955-7.*EHMT1*9q3412009q34 deletion syndrome2005J Med Genet. 2005; 42:299-306.*MECP2*Xq28400--800Intellectual Disability2005Am J Hum Genet. 2005; 77:442-53.*MAPT*17q21.3160017q21.31 microdeletion syndrome2006Nat Genet. 2006; 38:999-1001.*CHRNA7*15q13.3150015q13.3 microdeletion syndrome2008Nat Genet. 2008; 40:322-8.*MBD5*2q23.1200--40002q23.1 microdeletion syndrome2010Eur J Hum Genet. 2010; 18: 436-441.*NFIX*19p13.2100--200Sotos-like syndrome2010Am J Hum Genet. 2010; 87:189-98.*SHANK3*22q13.3100--9000Phelan-McDermid Syndrome2011Nature. 2011; 472: 437-42.*KANSL1*17q21.316817q21.31 microdeletion syndrome2012Nat Genet. 2012; 44:639-41.*ARIDIB*6q252500Intellectual Disability2012Am J Hum Genet. 2012; 90:565-72*KCTD13*16p11.2600Intellectual Disability2012Nature. 2012; 485:363-7.*TGFB2*1q416500Thoracic aortic aneurysm2012Nat Genet. 2012; 44:922-7.*KDM6A*Xp11.345--816Kabuki syndrome2012Am J Hum Genet. 2012; 90:119-24.

Both of our patients have eye problems. Patient 1 has strabismus which is typical findings in patients with Malan syndrome. Patinet 2 has congenital microphthalmia and heterochromia. The latter two symptoms are not commonly reported in Sotos syndrome. In addition, Patient 1 with Malan syndrome shows no heart defects, while Patient 2 has congenital heart disease that mostly associated with Sotos syndrome. Whether the cardiac defect of our Sotos syndrome patient is related to other deleted genes in this 5q35.2 deletion remains to be resolved.

Conclusion {#Sec10}
==========

In conclusion, we report two patients with overgrowth syndrome. Patient 1 is diagnosed as Malan syndrome with a 1.4 Mb 19p13.2-13.13 microdeletion including *NFIX*, while Patient 2 has Sotos syndrome with a 1.6 Mb 5q35.2 microdeletion encompassing *NSD1*. Our study contributes to the diagnosis and treatment of these diseases.
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ASD

:   Atrial septal defect

*CACNA1A*

:   Calcium voltage-gated channel subunit alpha1 A

*CALR*

:   Calreticulin

CGH

:   Comparative genomic hybridization

CHD

:   Congenital heart disease

*DNMT3A*

:   DNA methyltransferase 3 alpha

DQ

:   Developmental quotient

EEG

:   Electroencephalogram

*EZH2*

:   Enhancer of zeste 2 polycomb repressive complex 2 subunit

*FBN1*

:   Fibrillin 1

GWAS

:   Genome-wide association study

*NFIX*

:   Nuclear factor I X

*NSD1*

:   Nuclear receptor binding SET domain protein 1

OFC

:   Occipital frontal circumference

OGS

:   Overgrowth syndromes

OMIM

:   Online Mendelian Inheritance in Man

pCNVs

:   Pathogenic copy number variations

PDA

:   Patent ductus arteriosus

PHD

:   Plant homeodomain

*PTEN*

:   Phosphatase and tensin homolog

*SETD2*

:   SET domain containing 2

SNP

:   Single nucleotide polymorphism

WES/WGS

:   Whole exome/genome sequencing
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